Psychedelic substances have often been seen as outliers in scientific research—powerful and contentious, making them difficult to study. For many years, investigations into these compounds slowed, leaving unanswered questions about their impact on the brain.
However, as serious studies resurface, researchers are noticing an interesting trend: despite their varying characteristics, many prominent psychedelics seem to induce a similar underlying brain state.
This commonality might pave the way for a clearer understanding of a fragmented area of study, offering scientists a more uniform approach to exploring how these drugs could potentially enhance mental health treatments.
Five psychedelics, same brain patterns
Brain scans conducted during sessions involving psilocybin, LSD, mescaline, DMT, and ayahuasca revealed recurring altered patterns.
Research led by Danilo Bzdok from McGill University found that internal brain systems loosened up while distant systems communicated more actively.
While this discovery didn’t diminish the unique qualities of each drug, it did unveil a common framework beneath experiences traditionally regarded as distinct.
This clarity makes future questions more pointed, as researchers now need to explore what these dual changes actually do to the brain.
Brain networks break and reconnect
Functional connectivity in the brain—coordinated activity between regions over time—keeps various systems like visual and movement processes grouped. Under psychedelics, many of these internal connections weakened, resulting in networks that usually reinforce themselves becoming less cohesive.
Simultaneously, links between disparate networks strengthened, allowing sensory areas, decision-making circuits, and self-referential systems to engage more with one another.
This overlap may explain some of the unusual perceptions and rapid associations that individuals often report experiencing.
Bigger studies, better data
Earlier studies on psychedelics were usually small, often comprising only 10 to 30 participants. This limited size made distinguishing real trends from mere statistical noise quite challenging.
This time around, researchers took a much larger approach, merging 11 datasets from five different countries and analyzing over 500 brain scans from 267 individuals.
The increased scale significantly improved the analysis, enabling scientists to compare various drugs concurrently—something that would be tough for a single laboratory to achieve under rigid research regulations.
Bzdok noted, “This method provides us with an X-ray view of the entire research community.”
Brain patterns across psychedelics
Psilocybin and LSD exhibited the closest tracking, while mescaline generally aligned in patterns across major changes.
DMT tended to show more pronounced effects than both LSD and psilocybin, but the smaller sample size led to greater uncertainty regarding its reliability.
Ayahuasca often stood out due to its data deriving from a limited sample, which could explain its different patterns.
These variations are significant because the study indicated a core commonality, not evidence that all psychedelics generate the same brain state.
The brain isn’t breaking down
Historical studies often suggested psychedelics disrupt brain networks broadly, but this larger analysis provides a more nuanced view.
Rather than signaling a complete breakdown, the strongest evidence suggests increased communication among different brain networks.
The process involved using a Bayesian model—one that evaluates both strength and consistency—allowing researchers to identify which patterns genuinely repeat.
Deep brain changes
Particularly enhanced connectivity was noted in deeper brain regions such as the caudate and putamen, which connect sensation, action, and habit. These areas receive significant sensory and movement input, meaning stronger connections could shift how external signals influence behavior.
On the other hand, effects in the thalamus, a main relay center for incoming signals, appeared less consistent than previous smaller studies indicated.
Overall, the most pronounced shared pattern is likely found in circuits related to selection and coordination, rather than being evenly distributed throughout the brain.
Why this could help patients
While doctors don’t prescribe psychedelics based solely on brain scans, improved mapping may help design safer and more targeted treatment methods.
Current mental health medications often have widespread effects and take a while to show results. In contrast, psychedelics seem to alter brain activity by activating a critical serotonin-related mechanism.
Bzdok remarked, “Psychedelics may represent the most promising shift in mental health treatment since the 1980s.”
Yet, this potential is still tentative, as this research observed immediate brain changes in healthy individuals rather than tracking patient recovery.
Limitations of the study
All datasets came from healthy adults, so these findings don’t automatically apply to conditions like depression, addiction, or trauma.
Variations in scanning techniques, dosages, and timing post-dosing can obscure subtle effects despite thorough data cleaning.
Moreover, participants may move more while under the influence, which could falsely suggest unrelated brain areas are linked due to this motion.
These complications indicate that the shared pattern serves as a helpful reference point rather than a conclusive answer.
Psychedelics and human health
Psychedelic research nearly came to a halt after the 1970s due to criminalization and cultural biases, complicating rigorous study efforts.
With credible trials returning, researchers now need standardized measures to ensure that promising claims are backed by solid evidence.
Bzdok claimed, “For the first time, we present evidence of a common denominator across drugs currently viewed as distinct.”
This emerging understanding clarifies an otherwise crowded and often contradictory literature: psychedelics tend to reduce internal brain network order while enhancing communication among networks.
If subsequent studies continue to reflect this pattern, it could provide regulators and clinicians with a robust foundation for evaluating these drugs.
Ultimately, comprehensive and carefully matched trials in patients will determine whether this brain signature can forecast therapeutic benefits, side effects, or optimal dosages.
The study is published in the journal Nature Medicine.
